These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25231191)

  • 1. Antihyperglycaemic therapies and cancer risk.
    Lutz SZ; Staiger H; Fritsche A; Häring HU
    Diab Vasc Dis Res; 2014 Nov; 11(6):371-89. PubMed ID: 25231191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes drugs and the incidence of solid cancers: a survey of the current evidence.
    Tuccori M; Convertino I; Galiulo MT; Marino A; Capogrosso-Sansone A; Blandizzi C
    Expert Opin Drug Saf; 2017 Oct; 16(10):1133-1148. PubMed ID: 28748718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes mellitus and the risk of cancer.
    Pandey A; Forte V; Abdallah M; Alickaj A; Mahmud S; Asad S; McFarlane SI
    Minerva Endocrinol; 2011 Sep; 36(3):187-209. PubMed ID: 22019750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diabetes, insulin, insulin analogues, and cancer].
    Müssig K; Staiger H; Kantartzis K; Fritsche A; Kanz L; Häring HU
    Dtsch Med Wochenschr; 2010 May; 135(18):924-9. PubMed ID: 20425680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes.
    Chaudhuri A; Dandona P
    Diabetes Obes Metab; 2011 Oct; 13(10):869-79. PubMed ID: 21569185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinically important effects of oral antidiabetic drug interactions].
    Drzewoski J; Kopff B
    Pol Merkur Lekarski; 2000 Sep; 9(51):605-7. PubMed ID: 11126985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.
    Panicker GK; Karnad DR; Salvi V; Kothari S
    J Assoc Physicians India; 2012 Jan; 60():56-61. PubMed ID: 22715547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Safety of insulin analogues: what to evaluate, how to do it, and how to interpret the results].
    Hernández Mijares A; Solá Izquierdo E; García Malpartida K; Verge D
    Endocrinol Nutr; 2010 Oct; 57(8):376-80. PubMed ID: 20621572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs.
    McFarland MS; Cripps R
    Pharmacotherapy; 2010 Nov; 30(11):1159-78. PubMed ID: 20973689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes, antihyperglycemic medications and cancer risk: smoke or fire?
    Gallagher EJ; LeRoith D
    Curr Opin Endocrinol Diabetes Obes; 2013 Oct; 20(5):485-94. PubMed ID: 23974779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes.
    Lind M; Fahlén M; Eliasson B; Odén A
    Prim Care Diabetes; 2012 Apr; 6(1):53-9. PubMed ID: 22056422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidiabetic drugs and risk of cancer.
    Tokajuk A; Krzyżanowska-Grycel E; Tokajuk A; Grycel S; Sadowska A; Car H
    Pharmacol Rep; 2015 Dec; 67(6):1240-50. PubMed ID: 26481548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insulins and the risk of cancer.
    Danne T; Bolinder J
    Int J Clin Pract Suppl; 2010 Feb; (166):26-8. PubMed ID: 20377661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer risks from diabetes therapies: evaluating the evidence.
    Li C; Kong D
    Pharmacol Ther; 2014 Oct; 144(1):71-81. PubMed ID: 24844968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin analogues and cancer risk: cause for concern or cause célèbre?
    Pollak M; Russell-Jones D
    Int J Clin Pract; 2010 Apr; 64(5):628-36. PubMed ID: 20201993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Insulin and cancer: myth or reality?].
    Tran C; Gariani K; Philippe J
    Rev Med Suisse; 2010 Jun; 6(252):1188-90, 1192. PubMed ID: 20614753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy.
    Edwards KL; Riche DM; Stroup JS; Goldman-Levine JD; Padiyara RS; Cross LB; Kane MP
    Pharmacotherapy; 2010 Sep; 30(9):955-65. PubMed ID: 20795850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review on thiazolidinediones and bladder cancer in human studies.
    Tseng CH
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2014; 32(1):1-45. PubMed ID: 24598039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
    Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
    Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.